A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative ...

Wall Street sees plenty of growth ahead, projecting an 8.2% jump in sales for 2025 as new products gain traction ... dollar markets, Vertex offers a compelling mix of stability and upside potential.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Lately, one of America's leading pharmaceutical ... for Vertex Pharmaceuticals but this wouldn't be a transformative contribution. In November, the company reported third-quarter product sales ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...